Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does verapamil have a clinically significant antihypertensive effect?

O L Pedersen

    European Journal of Clinical Pharmacology
    |March 17, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Incidence of atrial fibrillation and thromboembolism in a randomised trial of atrial versus dual chamber pacing in 177 patients with sick sinus syndrome.

    Heart (British Cardiac Society)·2004
    Same author

    Serum hepatocyte growth factor levels in patients with chronic renal disease--effect of GFR and pathogenesis.

    Scandinavian journal of clinical and laboratory investigation·2002
    Same author

    Relation of left ventricular geometry and function to systemic hemodynamics in hypertension: the LIFE Study. Losartan Intervention For Endpoint Reduction in Hypertension Study.

    Journal of hypertension·2001
    Same author

    Serum cystatin C as an endogenous parameter of the renal function in patients with normal to moderately impaired kidney function.

    Clinical nephrology·2000
    Same author

    Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT)

    Lancet (London, England)·2000
    Same author

    Proximal tubular function in essential hypertensives on beta-blocker therapy with atenolol.

    Blood pressure·1997
    Same journal

    Efficacy and safety of Ensitrelvir in COVID-19 patients: a systematic review and meta-analysis with focus on viral clearance and RNA change.

    European journal of clinical pharmacology·2026
    Same journal

    Comparing National Health Technology Assessment approaches and the new European Joint Clinical Assessment framework: The case of onco-hematological medicines.

    European journal of clinical pharmacology·2026
    Same journal

    The efficacy of letrozole in the medical management of ectopic pregnancy: a systematic review and meta-analysis.

    European journal of clinical pharmacology·2026
    Same journal

    Detection of intravenous drug physicochemical incompatibilities in clinical practice: e-Harvis compared to reference tools.

    European journal of clinical pharmacology·2026
    Same journal

    Efficacy and safety of doravirine/islatravir for the treatment of HIV-1: a systematic review and meta-analysis of randomized controlled trials with GRADE assessment.

    European journal of clinical pharmacology·2026
    Same journal

    Critical analysis of digitalis glycosides: declining use but increasing poison-center exposure cases for digitoxin.

    European journal of clinical pharmacology·2026
    See all related articles

    Verapamil showed a modest effect in lowering blood pressure during a pilot study. This calcium channel blocker is not recommended for treating arterial hypertension due to limited efficacy.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Arterial hypertension is a significant risk factor for cardiovascular disease.
    • Calcium channel blockers are a class of drugs used to manage hypertension.
    • Verapamil, a non-dihydropyridine calcium channel blocker, has been investigated for its antihypertensive properties.

    Purpose of the Study:

    • To evaluate the efficacy and safety of verapamil as an antihypertensive agent in a pilot study.
    • To assess the effects of intravenous and oral verapamil on blood pressure and cardiovascular parameters.

    Main Methods:

    • Pilot study involving intravenous administration of verapamil (0.1 mg/kg bolus followed by 0.0035 mg/kg/min infusion).
    • Subsequent oral administration of verapamil (320-640 mg daily for 7 weeks) in five patients.
    • Monitoring of systolic and diastolic blood pressure, heart rate, and atrio-ventricular conduction time.

    Related Experiment Videos

    Main Results:

    • Intravenous verapamil significantly reduced blood pressure (maximal average decrease of 23/16 mm Hg) but increased heart rate and prolonged atrio-ventricular conduction.
    • Oral verapamil resulted in a modest blood pressure reduction (mean 14/12 mm Hg) in four out of five patients, without achieving normotension.
    • Oral verapamil did not alter atrio-ventricular conduction time and decreased resting pulse rate; side effects included flushing.

    Conclusions:

    • Verapamil demonstrates a modest antihypertensive effect.
    • The drug is not considered suitable for the treatment of arterial hypertension based on this pilot study.
    • Further research may be needed to explore alternative applications or formulations of verapamil.